Today’s Solutions: September 13, 2026

Women receive only a slim 2 percent of venture capital funds, but Anthemis and Barclays’, Female Innovator Lab, is looking to change this statistic. The New York-based group is looking to back female financial technology startups to level the playing field for female entrepreneurs. 

The group assesses each startup’s needs and works as not just a backer, but a partner and support system as well. Anthemis cofounder, Amy Nauiokas, says many women leave the financial industry, not because of family commitments or lack of talent, but because opportunities for mobility in the industry are limited. For many women, the support is just not the same as for their male counterparts. 

Managing over $380 million in assets, Anthemis is well equipped to handle challenges specific to the industry and thinks traditionally underfunded groups are the key to new innovation in the field of financial technology. Nauiokas says, “As far as I’m concerned, we need to make sure that every company we help create, every company we fund, and every business we build becomes in itself a kind of petri dish for diversity and inclusion.”

Solutions News Source Print this article
More of Today's Solutions

Pittsburgh will become a dark sky city in 2022

Anyone who lives in a big city knows that stars are a rare sight due to light pollution, but that may soon change in ...

Read More

“Shy girl workouts” are helping women build confidence in the gym

In a society overrun with fitness fads, there is one new phenomenon that is having a particularly positive impact on women's fitness journeys. Meet ...

Read More

Exposing the hidden threat: skin absorption of indoor air pollutants

Indoor spaces, where many of us spend the majority of our lives, conceal a hidden threat: contaminants that enter not only through the air ...

Read More

A major first in malaria care: newborn treatment approved for use in Africa

BY THE OPTIMIST DAILY EDITORIAL TEAM For the first time ever, newborn babies have a malaria treatment made just for them. Swissmedic, Switzerland’s drug ...

Read More